SCHEMBL5229885

SCHEMBL5229885

CCOc1cc(N2CCN(C)CC2)ccc1-c1nc2c(C)nn(-c3ccccc3)c2c(=O)[nH]1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 14/20 0.58
PDE7A Q13946 2/20 0.51
KHK P50053 2/20 0.47
PDE1A P54750 4/20 0.47
PDE1B Q01064 4/20 0.47
PDE1C Q14123 4/20 0.47
KDM4E B2RXH2 1/20 0.47
MEN1 O00255 1/20 0.47
ALDH1A1 P00352 1/20 0.47
HPGD P15428 1/20 0.47
KMT2A Q03164 1/20 0.47
HDAC1 Q13547 3/20 0.44
HDAC6 Q9UBN7 3/20 0.44
PDE2A O00408 1/20 0.44
ABCC4 O15439 1/20 0.44
ABCC5 O15440 1/20 0.44
PDE6D O43924 1/20 0.44
PDE8A O60658 1/20 0.44
PDE9A O76083 1/20 0.44
ABCB11 O95342 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5233408 0.91 PDE5A (0.55) PDE5APDE7AKHKPDE1APDE1B
SCHEMBL5228298 0.91 PDE5A (0.55) PDE5APDE7APDE1APDE1BPDE1C
SCHEMBL5235453 0.91 PDE7A (0.48) PDE5APDE7AKHKKDM4EALDH1A1
SCHEMBL5234533 0.89 PDE7A (0.54) PDE5APDE7APDE1APDE1BPDE1C
SCHEMBL5231978 0.89 PDE5A (0.53) PDE5APDE7APDE1APDE1BPDE1C
SCHEMBL5233119 0.88 PDE5A (0.51) PDE5APDE7APDE1APDE1BPDE1C
SCHEMBL5231475 0.88 PDE5A (0.51) PDE5APDE7APDE1APDE1BPDE1C
SCHEMBL5232898 0.87 PDE5A (0.51) PDE5APDE7APDE1APDE1BPDE1C
SCHEMBL5234114 0.87 PDE5A (0.51) PDE5APDE7APDE1APDE1BPDE1C
SCHEMBL1819682 0.85 PDE5A (0.50) PDE5APDE7AKHKPDE1APDE1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1454897-B1 PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7-INHIBITORY ACTIVITY ASUBIO PHARMA CO LTD (JP) 2007-10-10 EP disclosed
US-7268128-B2 1,3,5-trisubstituted-5-phenyl and 5-pyridyl pyrazolopyrimidinone derivatives having PDE7 inhibiting action AUSBIO PHARMA CO., LTD. (JP) 2007-09-11 US disclosed
US-20050148604-A1 Pyrazolopyrimidinone derivatives having PDE7 inhibiting action OMEROS CORPORATION 2005-07-07 US disclosed
EP-1454897-A1 PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7−INHIBITORY ACTIVITY Daiichi Suntory Pharma Co., Ltd. (JP) 2004-09-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148604-A1 Pyrazolopyrimidinone derivatives having PDE7 inhibiting action PDE7B, PDE3B, PDE3A PDE5A 8/4885PDE7A 4/4885KHK 2017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.